NCT05228470: Phase 2: MagnetisMM-8: Study Of Elranatamab (PF-06863135) Monotherapy in China RRMM
Updated: Feb 7
MagnetisMM-8
NCT05228470: Phase 2: MagnetisMM-8: Study Of Elranatamab (PF-06863135) Monotherapy in Chinese Participants With Refractory Multiple Myeloma
MagnetisMM-8: Study Of Elranatamab (PF-06863135) Monotherapy in Chinese Participants With Refractory Multiple Myeloma
Study C1071008 includes 2 parts. The objective of Phase 1b part is to establish the safety profile in order to confirm the monotherapy RP2D in Chinese participants. The Phase 2 part is a single stage design to evaluate the efficacy and safety in Chinese participants. Elranatamab is a bispecific antibody: binding of Elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.
Sponsor
Pfizer
Location
China
ClinicalTrials.gov Identifier: NCT05228470
Official Title: A PHASE 1B/2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF ELRANATAMAB (PF-06863135) IN CHINESE PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY
First Posted : February 8, 2022
Click here for details on Clinicaltrials.gov
Elranatamab (Code C146860)
Anti-CD3/Anti-BCMA Bispecific Antibody PF-06863135
B-cell Maturation Antigen-CD3 Bispecific Antibody PF-06863135
BCMA x CD3 Bispecific Antibody PF-06863135
BCMA-CD3 Bispecific Ab PF-06863135
Elranatamab
ELRANATAMAB
PF 06863135
PF-06863135
PF06863135
RN 613
RN-613
RN613
Locations
China
China, Fujian
China, Guangdong
China, Heilongjiang
China, Jiangsu
China, Shandong